Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: Report of two cases

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Nagao, Azusa ^a   Nakazawa, Shoko ^a   Hanabusa, Hideji ^a  

^a Ogikubo Hospital   (Japan)

Author keywords

Castleman disease; HHV8; HIV MCD; IL6; Tocilizumab

Indexed keywords

INTERLEUKIN 6; TOCILIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG EFFICACY; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHADENOPATHY; MALE; MIDDLE AGED; RELAPSE; REMISSION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; GIANT LYMPH NODE HYPERPLASIA; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892448928     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-10     Document Type: Article

References (8)

1. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z, Clin Adv Hematol Oncol 2010 8 486 498 20864917
2. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T, Blood 2005 106 2627 2632 10.1182/blood-2004-12-4602 15998837 (Pubitemid 41510733)
3. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M, Ann Oncol 2009 20 775 779 10.1093/annonc/mdn697 19179554
4. HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, Janz S, Scheller J, Rose-John S, Blood 2012 119 5173 5181 10.1182/blood-2011-09-377705 22490805
5. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Polizzotto MN, Uldrick TS, Victoria W, Karen A, Wyvill KM, Vickie M, Stefania P, Deirdre O'M, Denise W, Giovanna T, Steinberg SM, Little RF, Robert Y, Blood 2013 122 4189 4198 10.1182/blood-2013-08-519959 24174627
6. Prospective study of Rituximab in chemotherapy- dependent human immunodeficiency cirus-associated multicentric castleman's disease: ANRS117 castlemaB trial. Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E, J Clin Oncol 2007 25 3350 3356 10.1200/JCO.2007.10.6732 17664482 (Pubitemid 47325622)
7. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Gérard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbalika F, Chevret S, Oksenhendler E, Galicier L, Blood 2012 119 2228 2233 10.1182/blood-2011-08-376012 22223822
8. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P, Ann Intern Med 2007 147 836 839 10.7326/0003-4819-147-12-200712180-00003 18087054 (Pubitemid 351664423)